Your browser doesn't support javascript.
loading
Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders.
Boffa, M B; Nesheim, M E; Koschinsky, M L.
Affiliation
  • Boffa MB; Departments of Biochemistry and Medicine, Queen's University, Kingston, Ontario, Canada K7M 8X3.
Curr Drug Targets Cardiovasc Haematol Disord ; 1(2): 59-74, 2001 Dec.
Article in En | MEDLINE | ID: mdl-12769657
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Carboxypeptidase B2 Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Curr Drug Targets Cardiovasc Haematol Disord Journal subject: ANGIOLOGIA / CARDIOLOGIA / HEMATOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2001 Document type: Article
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Carboxypeptidase B2 Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Curr Drug Targets Cardiovasc Haematol Disord Journal subject: ANGIOLOGIA / CARDIOLOGIA / HEMATOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2001 Document type: Article